The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan

Journal of Medical Economics

Volumn 21, Issue 5, 2018, Pages 488-496

  Ishii, Hitoshi ^a   Madin Warburton, Matthew ^b   Strizek, Alena ^c   Thornton Jones, Lucy ^b   Suzuki, Shuichi ^d  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b IQVIA   (United States)

^c Eli Lilly Australia   (Australia)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

cost effectiveness; dulaglutide; insulin glargine; Japan; Type 2 diabetes

Indexed keywords

CHOLESTEROL; DULAGLUTIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; FUSION PROTEIN; GLUCAGON LIKE PEPTIDE; GLYCOSYLATED HEMOGLOBIN; IMMUNOGLOBULIN FC FRAGMENT; LIPID;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DRUG COST; DRUG EFFECT; EYE DISEASE; FEMALE; HEALTH CARE COST; HUMAN; JAPANESE (PEOPLE); KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULCER; AGED; ANALOGS AND DERIVATIVES; BLOOD; COST BENEFIT ANALYSIS; DIABETIC COMPLICATION; DISEASE EXACERBATION; ECONOMICS; HEALTH BEHAVIOR; JAPAN; LIFE EXPECTANCY; QUALITY OF LIFE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BODY MASS INDEX; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCAGON-LIKE PEPTIDES; GLYCATED HEMOGLOBIN A; HEALTH BEHAVIOR; HEALTH EXPENDITURES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN GLARGINE; JAPAN; LIFE EXPECTANCY; LIPIDS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT FUSION PROTEINS;

EID: 85041498078     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.1080/13696998.2018.1431918     Document Type: Article

References (62)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(suppl1):S5-S10
2. World Health Organization. WHO | World Health Day 2016: Beat diabetes [Internet]. Geneva: WHO; 2016. Available at: http://www.who.int/campaigns/world-health-day/2016/en/
3. International Diabetes Federation. IDF Diabetes Atlas. 7th edn. Brussels: IDF; 2015. 144 p
4. Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
5. Goto A, Goto M, Noda M, et al. Incidence of type 2 diabetes in Japan: a systematic review and meta-analysis. PLoS One 2013;8:e74699
6. Reich MR, Shibuya K., The future of Japan’s health system—sustaining good health with equity at low cost. N Engl J Med 2015;373:1793-7
7. International Diabetes Federation. Japan | International Diabetes Federation [Internet]. Brussels 2016. Available at: http://www.idf.org/membership/wp/japan
8. Neville SE, Boye KS, Montgomery WS, et al. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705-16
9. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
11. Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013;19:421-30
12. Ministry of Health Labour and Welfare. Central Social Insurance Medical Council (Central Social Insurance Medical Council cost-effectiveness evaluation Expert Group) [Internet]. Tokyo: Ministry of Health Labour and Welfare. 2016 Available at: http://www.mhlw.go.jp/stf/shingi/shingi-chuo.html?tid = 128159
13. Shiroiwa T, Fukuda T, Ikeda S, et al. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health 2017;20:372-8
14. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015;385:2057-66
15. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384:1349-57
16. Giorgino F, Benroubi M, Sun J-H, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015;38:2241-9
17. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37:2149-58
18. Umpierrez G, Tofé Povedano S, Pérez Manghi F, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014;37:2168-76
19. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014;37:2159-67
20. Eli Lilly and Company. A study comparing the effect of dulaglutide with liraglutide in type 2 diabetes (AWARD-6) [Internet]. Indianapolis: Eli Lilly and Company; 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01624259
21. Araki E, Inagaki N, Tanizawa Y, et al. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab 2015;17:994-1002
22. Miyagawa J, Odawara M, Takamura T, et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab 2015;17:974-83
23. McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health 2014;17:714-24
24. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia 2004;47:1747-59
25. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12
26. Yang X, So W-Y, Kong APS, et al. Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2007;30:65-70
27. Fukuda T, Shiroiwa T, Ikeda S, et al. Guideline for economic evaluation of healthcare technologies in Japan. J Natl Inst Public Health 2013;62:625-40
28. WHO. WHO report on the global tobacco epidemic, 2015. Geneva: WHO; 2015
29. WHO. Alcohol consumption: level and patterns. Geneva: WHO; 2014
30. NICE. Type 2 diabetes in adults: management [Internet]. London: NICE; 2016. Available at: https://www.nice.org.uk/guidance/ng28?unlid = 8655184232016320125634
31. Inoue K, Maeda N, Fujishima Y, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr 2014;6:95
32. Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17:462-70.
33. Ikeda S, Kobayashi M., Cost-effectiveness analysis of metformin or pioglitazone combined with sulfonylurea in type 2 diabetes mellitus in Japan. Journal of the Japan Diabetes Society 2010;53:469-75
34. Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 2011;12:219-30
35. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251-65
36. Ministry of Health Labour and Welfare. MHLW medical payment fee system list [Internet]. Tokyo: Ministry of Health Labour and Welfare; 2016. Available at: http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000106421.html
37. Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 2010;20:413-19
38. Japan Medical Data Center. Claims Database [Internet]. Tokyo; JMDC 2016. Available at: https://www.jmdc.co.jp/
39. XE.com. JPY - Japanese Yen rates [Internet]. Newmarket, Canada: XE.com; 2016. Available at: http://www.xe.com/currency/jpy-japanese-yen
40. E-Stat. Portal site of official statistics of Japan [Internet]. Tokyo: E-Stat; 2016. p. Section 1-1. Available at: http://www.e-stat.go.jp/SG1/estat/ListE.do?lid = 000001147915
41. Curtis L., Unit costs of health & social care 2014 [Internet]. PSSRU: Personal Social Services Research Unit; 2014. p. 1-292. Available at: http://www.pssru.ac.uk/project-pages/unit-costs/2014/index.php
42. Ikeda S, Kobayashi M, Tajima N., Cost-effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance. J Diabetes Investig 2010;1:252-8
43. Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
44. Tamura H, Goto R, Akune Y, et al. The clinical effectiveness and cost-effectiveness of screening for age-related macular degeneration in Japan: a Markov modeling study. PLoS One 2015;10:e0133628
45. Tanaka S, Tanaka S, Iimuro S, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care 2013;36:1193-9
46. Saokaew S, Sugimoto T, Kamae I, et al. Healthcare databases in Thailand and Japan: potential sources for health technology assessment research. PLoS One 2015;10:e0141993
47. Tanaka S, Seto K, Kawakami K, et al. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Heal Care Sci 2015;1:16
48. Kerr M, Rayman G, Jeffcoate WJ., Cost of diabetic foot disease to the National Health Service in England. Diabet Med 2014;31:1498-504
49. Ghatnekar O, Willis M, Persson U., Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care 2002;11:70-4
50. Kimura M, Nakayasu K, Ohshima Y, et al. SS-MIX: a ministry project to promote standardized healthcare information exchange. Methods Inf Med 2011;50:131-9
51. NHI reimbursement price list [Internet]. Tokyo: NHI; 2016. Available at: http://www.mhlw.go.jp/topics/2016/04/tp20160401-01.html
52. Diabetes Network. How much will it cost if you get diabetes? [Internet]. Tokyo; Soshinsha 2016. Available at: http://www.dm-net.co.jp/seido/02/
53. Evans E, Imanaka Y, Sekimoto M, et al. Risk adjusted resource utilization for AMI patients treated in Japanese hospitals. Health Econ 2007;16:347-59
54. Tanihata S, Nishigaki K, Kawasaki M, et al. Outcomes of patients with stable low-risk coronary artery disease receiving medical- and PCI-preceding therapies in Japan: J-SAP study 1-1. Circ J 2006;70:365-9
55. Saito I, Kobayashi M, Matsushita Y, et al. Pharmacoeconomical evaluation of combination therapy for lifetime hypertension treatment in Japan. JMAJ 2005;48:574-85
56. Oshima S, Ogawa H, Nakao K, et al. Cost of illness in peripheral artery disease and the related cardiovascular events. J New Rem Clin 2013;62:150-68
57. Fukuda H, Ikeda S, Shiroiwa T, et al. The effects of diagnostic definitions in claims data on healthcare cost estimates: evidence from a large-scale panel data analysis of diabetes care in Japan. Pharmacoeconomics 2016;34:1005-14
58. Kitazawa T, Matsumoto K, Fujita S, et al. Cost of renal transplantation and the development of infections in Japan - an analysis based on the national claim database. 17th Japan Society for Health Care Management; June 13, 2015. Tokyo, Japan
59. Nakatani T, Uchida J, Nitta Y, et al. Health economics of the treatments, transplantation/dialysis, for chronic renal failure. Transplantation Now 2010;23:143-48
60. Mano T., Cost of illness in the hypoglycemia event among patients with diabetes. J New Rem Clin 2012;61:2247-58
61. Hiratsuka Y, Yamada M, Murakami A, et al. Cost-effectiveness of cataract surgery in Japan. Jpn J Ophthalmol 2011;55:333-42
62. Zimny S, Voigt A, Schatz H, et al. Prediction of wound radius reductions and healing times in neuropathic diabetic foot ulcers. Diabetes Care 2003;26:959-60